Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Spark Plus Singapore Healthcare Day 2024
31 slides from Arovella Therapeutics's conference presentation, Mar 14, 2024
Slide 1: Spark Plus Singapore Healthcare Day Presentation (ASX Release)
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 14 March 2024 SPARK PLUS SINGAPORE HEALTHCARE DAY PRESENTATION Highlights: • Arovella presents at Spark Plus Singapore Healthcare Day MELBOURNE, AUSTRALIA 14 March 2024: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company F
Slide 2: Notes to Editors: About Arovella Therapeutics
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 NOTES TO EDITORS: About Arovella Therapeutics Ltd Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cance
Slide 3: Investor Presentation, Singapore Healthcare Day
ASX:ALA For personal use only Investor Presentation Singapore Healthcare Day March 2024
Slide 4: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment 4. Whilst this presentation is based on information from sources which are advice. The presentation is not intended to be comprehensive or provide all considered reliable, no representation or warranty, expres
Slide 5: Arovella's strengths
Arovella’s strengths Off-the-shelf iNKT Lead Product Addressing Key Strong For personal use only Cell Platform Advancing to Clinic Unmet Need Leadership Group Developing off-the-shelf iNKT ALA-101, a potential treatment Our iNKT cell platform is Leadership team and Board cell therapies to target blo
Slide 6: Financial overview
Financial overview Financial Snapshot ALA Price and Volume - 12 Months1 ASX CODE ALA $0.20 For personal use only Market capitalisation1 $143.4 million 40,000,000 $0.18 Shares on issue 925.1 million $0.16 52-week low / high1 $0.033 / $0.185 $0.14 30,000,000 Cash Balance (Dec 31 2023) $4.76 million $0
Slide 7: Recent cell therapy transactions
Recent cell therapy transactions1 Upfront Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Cell Type Stage (US$M) (US$M) value (US$M) Dec-23 Acquisition T Cell Phase 1b $1,000 $200 $1,200 Collaboration and $70-220 per For personal use only Nov-23 Not specified Platform $25 i
Slide 8: How original CAR-T cell therapies work
How original CAR-T cell therapies work CAR-T cell therapy is personalised medicine T cells = immune cell For personal use only - T cells are a common type of immune cell that fight infections and can help fight cancer. T cells from patient ‘reprogrammed’ - - To generate autologous CAR-T cells, T cel
Slide 9: Cell Therapy has revolutionised blood cancer treatment
Cell Therapy has revolutionised blood cancer treatment CAR-T cells have demonstrated their curative potential in blood cancers For personal use only Product Approval Year 2023 Revenue Cure CAR-T cells have 2017 US$1498m3 demonstrated ability to cure haematological 2017 US$509m4 cancers 2021 US$472
Slide 10: Emily Whitehead - Celebrating years of CAR-T cell therapy
For personal use only Emily Whitehead - Celebrating 10 years of CAR-T cell therapy https://emilywhiteheadfoundation.org/10-years-of-car-t/ ASX:ALA 8
Slide 11: Autologous CAR-T pose challenges
Autologous CAR-T pose challenges Allogeneic The current manufacturing costs and time are limiting A single healthy donor Manufacturing & supply batch = treatment for For personal use only T cell chain costs are high multiple patients T cell Each T cells can be manufacturing compromised T cell batch
Slide 12: Introducing invariant Natural Killer T (iNKT) cells
Introducing invariant Natural Killer T (iNKT) cells Bridging the innate and adaptive immune system For personal use only Innate Immunity Adaptive Immunity ASX:ALA 10
Slide 13: iNKT cells represent a next-generation cell therapy
iNKT cells represent a next-generation cell therapy Properties make them ideal for use in cell therapy Strong safety profile For personal use only Don’t cause graft versus host disease (GvHD) Innate Front line of the human Immunity immune system Bridge innate & adaptive immune responses Contai
Slide 14: A differentiated position
A differentiated position T cell and NK cell sectors are competitive For personal use only T cell iNKT cell NK cell Companies with T cell, NK cell, or iNKT cell therapy programs. Source: Company analysis based on public information ASX:ALA 12
Slide 15: CAR-iNKT cell therapy production advantages
CAR-iNKT cell therapy production advantages Off-the-shelf manufacturing advantages MANUFACTURING For personal use only Isolate iNKT cells Expand to grow billions of CAR-iNKT cells Collect Healthy Engineer iNKT cells Vial and freeze Donor Blood to produce a CAR CAR-iNKT cells TREATMENT Thaw CAR-iNKT
Slide 16: ALA-101 (CAR19-iNKT cells)
For personal use only ALA-101 (CAR19-iNKT cells) A next generation off-the-shelf cell therapy for CD19 expressing cancers 14
Slide 17: ALA-101: enhanced tumour killing in vivo
ALA-101: enhanced tumour killing in vivo ALA-101 rapidly eradicates tumour cells in mice Tumour cells expressing CD19 and PBS T iNKT CAR19-T ALA-101 For personal use only CD1d were intravenously delivered into mice Ventral Mice were treated with: PBS (saline) Day 0 Unmodified T cells (T) Dor
Slide 18: ALA-101: next generation cell therapy
ALA-101: next generation cell therapy ALA-101 significantly increased survival in mice versus treatment with CAR19-T cells Tumour cells expressing CD19 and CD1d For personal use only were intravenously delivered into mice Mice were treated with: P <0.01 PBS (saline) Unmodified T cells (T)
Slide 19: ALA-101: spontaneous secondary remission
ALA-101: spontaneous secondary remission ALA-101 activity may persist to eradicate tumour cells following relapse For personal use only Four mice treated with ALA-101 Ventral had the cancer return to the brain In all four mice, the cancer was eliminated a second time with no Dorsal additional do
Slide 20: Progress towards first-in-human clinical trials
Progress towards first-in-human clinical trials ALA-101 data confirms activity and off-the-shelf capability For personal use only Potent antitumour Expected to Multiple dose activity be safe manufacturing Phase 1 clinical trial Demonstrated efficacy of ALA-101 against CD19+ iNKT cells have been show
Slide 21: iNKT cells to target solid tumours
iNKT cells to target solid tumours For personal use only Arovella is implementing its strategy to target and kill solid tumours – 90% of newly diagnosed cancer cases1 1. https://www.cancer.gov/types/common-cancers 19
Slide 22: Solid tumours pose challenges to cell therapies
Solid tumours pose challenges to cell therapies For personal use only Solid tumours are more difficult to treat with cell therapies Access to tumour Antigen specificity iNKT cells: and uniformity Home to tissues and infiltrate tumours Tumour microenvironment Modify the TME to block or kill cells tha
Slide 23: Arovella's strategies to combat solid tumours
Arovella’s strategies to combat solid tumours Arovella is using three approaches to expand the iNKT cell platform into solid tumours For personal use only License novel Armour Create unique cancer targets iNKT cells partnerships Identify and license Enhance the Create partnerships new targets that a
Slide 24: Add additional CARs for novel targets
STRATEGY 1 Add additional CARs for novel targets Arovella’s manufacturing process can be leveraged for multiple cancer types MANUFACTURING For personal use only Isolate iNKT cells Expand to grow billions of CAR-iNKT cells Collect Healthy Engineer iNKT cells Vial and freeze Donor Blood to produce a C
Slide 25: Introducing Claudin 18.2 (CLDN18.2)
Introducing Claudin 18.2 (CLDN18.2) A promising solid tumour target For personal use only CLDN18.2 overexpression has been Validated target identified in several with first monoclonal antibody expected to be approved in types of cancers 2024 gastric cancer (GC) gastroesophageal junction cancer (GEJC
Slide 26: "Armouring" CAR-iNKT cells
STRATEGY 2 “Armouring” CAR-iNKT cells IL-12-TM (cytokine technology) enhances CAR-iNKT cell activity in solid tumours For personal use only iNKT cells IL-12-TM IL-12-TM Expand more 10x more Superior and survive circulating anti-tumour for longer CAR-iNKT cells activity IL-12-TM is a modified version
Slide 27: Arovella's expanding pipeline
Arovella’s expanding pipeline CD19-CAR CD19-CAR Novel Targets Introduction of CLDN18.2 For personal use only ALA-101 ALA-101 + onCARlytics CLDN18.2 IL-12-TM Non-Hodgkin’s Head and Prostate Brain Triple negative Pancreatic Gastric Lung Cancer Lymphoma Neck Cancer Cancer Metastases breast cancer Cance
Slide 28: Upcoming milestones for 2024
Upcoming milestones for 2024 January July December 2024 2024 2024 For personal use only Complete cGMP manufacture for Phase 1 clinical trials Commence Phase 1 for ALA-101 targeting CD19+ ALA-101 Complete preparatory activities for Phase 1 study, lymphoma and leukemia (CD19) including preparati
Slide 29: Summary
Summary Novel allogeneic Lead product progressing CAR-iNKT cell platform to clinical trials For personal use only iNKT cells serve as an excellent platform ALA-101, a potential treatment for to develop allogeneic, or “off-the-shelf”, CD19-expressing blood cancers, is cell therapies to treat cancer b
Slide 30: Thank You
ASX:ALA For personal use only Thank You Dr. Michael Baker CEO & Managing Director Email: investor@arovella.com Mobile: +61 403 468 187
Slide 31: Cell therapy deal references
Cell therapy deal references 1. https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and- autoimmune-diseases.html 2. https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-cell-and-gene-therapy
Arovella Therapeutics — Spark Plus Singapore Healthcare Day 2024 on 6ix